Caloric intake influences the onset of many diseases, including cancer. In particular, caloric restriction (CR) has been reported to suppress mammary tumorigenesis in various models. However, the underlying cancer preventive mechanisms have not been fully explored. To this end, we aimed to characterize the anticancer mechanisms of CR using MMTV-ErbB2 transgenic mice, a well-established spontaneous ErbB2-overexpressing mammary tumor model, by focusing on cellular and molecular changes in premalignant tissues. In MMTV-ErbB2 mice with 30% CR beginning at 8 weeks of age, mammary tumor development was dramatically inhibited, as exhibited by reduced tumor incidence and increased tumor latency. Morphogenic mammary gland analyses in 15-and 20-week-old mice indicated that CR significantly decreased mammary epithelial cell (MEC) density and proliferative index. To understand the underlying mechanisms, we analyzed the effects of CR on mammary stem/progenitor cells. Results from fluorescence-activated cell sorting analyses showed that CR modified mammary tissue hierarchy dynamics, as evidenced by decreased luminal cells (CD24 ). Mammosphere and colony-forming cell assays demonstrated that CR significantly inhibited mammary stem cell self-renewal and progenitor cell numbers. Molecular analyses indicated that CR concurrently inhibited estrogen receptor (ER) and ErbB2 signaling. These molecular changes were accompanied by decreased mRNA levels of ER-targeted genes and epidermal growth factor receptor/ErbB2 family members and ligands, suggesting ER-ErbB2 signaling cross-talk. Collectively, our data demonstrate that CR significantly impacts ER and ErbB2 signaling, which induces profound changes in MEC reprogramming, and mammary stem/progenitor cell inhibition is a critical mechanism of CR-mediated breast cancer prevention.
Introduction
Diet as a factor that may influence breast cancer risk has been studied to identify possible preventive and management options. As such, energy homeostasis is necessary for glucose metabolism; however, caloric restriction (CR) has been explored as a possible means to impede metabolism and thereby inhibit growth in tumor cells (1) (2) (3) (4) (5) . CR is achieved by limiting caloric intake, yet avoiding malnutrition by consuming adequate nutrients. A meta-analysis performed by Dirx et al. (6) , comparing 14 studies that tested the effects of CR on multiple spontaneous mammary tumor models, found that ~30-50% CR effectively inhibited tumorigenesis in mice. The preventive nature of CR on age-related cancers has been reported in rhesus monkeys as well (7) . In addition to CR alone, studies have shown that alternative interventions combining CR with other chemotherapies also decrease established tumors and metastases associated with multiple cancers (8) (9) (10) . Reports by Saleh et al. (8) and Simone et al. (9) demonstrated that the combination of 30% CR and ionizing radiation significantly reduced triple-negative breast cancer tumor growth and lung metastases with inhibitory effects on insulin-like growth factor-1 receptor (IGF1R) signaling. Similarly, Galet et al. (10) investigated the effects of 40% CR in a model of prostate cancer to find that CR acted synergistically with ganitumab, an IGF1R antibody, to decrease tumor growth. However, they found that CR did not significantly alter IGF1R expression (10) . Taken together, many studies demonstrate the anticancer benefits of CR; nevertheless, the underlying mechanisms involved in breast cancer prevention remain unclear.
CR negatively regulates hormonal and other signaling pathways that promote carcinogenesis as compared to ad libitum-fed or obese control animals (11, 12) . Previous studies have reported that sex hormones, particularly estrogen, are modulated in response to changes in energy balance (11, 13) . For instance, Li et al. (11) showed that 25 and 45% CR resulted in a dose-and time-specific reduction of estrogen levels in Sprague-Dawley rats. Physiological levels of estrogen are necessary for typical mammary development; however, elevated levels of circulating estrogen have been associated with obesity due to the increased production of estrogen in adipose tissue (14, 15) . In turn, obesity and aberrantly high levels of estrogen are linked to an increased incidence of breast cancer in women (15) (16) (17) (18) . Estrogen receptor (ER) signaling is known to upregulate cell proliferation through transcriptional regulation of target genes, including Cyclin D1, which can drive the cell cycle through checkpoints and lead to an accumulation of DNA errors (19) . Potentially cancerous cells and tissues can develop from DNA mutations that remain unrepaired due to non-functioning repair mechanisms or apoptotic pathways; therefore, estrogen modulation has been identified as an important target of many breast cancer therapies, such as tamoxifen. To find other anticancer strategies with improved clinical outcomes, the hormone-modulating potential of CR needs to be further characterized.
The effects of CR on ErbB2 (Her2/neu) expression and downstream signaling are also particularly intriguing because ~20-30% of mammary tumors overexpress ErbB2 (20) . The overexpression/gene amplification of ErbB2 is also correlated with poor prognosis, making the prevention and treatment of this breast cancer subtype a substantial clinical problem and a promising anticancer target. ErbB2 belongs to the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTKs) and phosphorylates/activates downstream PI3K/Akt, MAPK and mTOR signaling pathways involved in cell survival, proliferation, glucose metabolism and protein translation (21, 22) . Regulation of these pathways has been the target for many anticancer drug therapies, but CR offers a novel preventive and/or therapeutic strategy without consequential side effects. An initial report by Mizuno et al. (23) provided evidence that 25% CR can increase tumor latency in MMTV-ErbB2 mice; however, the underlying anticancer mechanism exerted in response to CR has not been fully explored. The MMTV-ErbB2 transgenic mouse model is an ideal system to study the effects of dietary interventions, including CR, for the prevention of ErbB2-overexpressing breast cancers due to its well-defined genetic background and its clinical relevance to women who are at a high risk for developing ErbB2 + breast cancer. Mammary stem cells (MaSCs), which are important in mammary gland development and can be regulated by ErbB2 downstream signal transduction, are also capable of promoting carcinogenesis via oncogenic transformation into cancer stem cells (CSCs) (24) (25) (26) (27) . Therefore, we hypothesized that the potential modulation of ErbB2 signaling by CR would diminish the MaSC population in MMTV-ErbB2 transgenic mice. In support of our hypothesis, metformin, which we have previously demonstrated to target tumor-initiating cells (TICs)/CSCs (28, 29) , activates AMPK and is considered an energy restriction mimetic. It is thought that CR and mimetics exert control on MaSCs/CSCs through the downregulation of mitochondrial biogenesis and multi-faceted inhibition of mTOR-mediated protein translation (30, 31) . Likewise, the aim of our study is to highlight the underlying regulatory mechanisms that contribute to the anticancer properties of CR.
In our current study, 30% CR beginning at 8 weeks of age, coinciding with the onset of puberty and continuing throughout the 'risk window' for mammary tumor development in MMTVErbB2 transgenic mice, significantly inhibited tumorigenesis by 60 weeks of age as compared to the ad libitum-fed control mice. Our work fundamentally corroborates previous studies that CR prevents mammary carcinogenesis in MMTV-ErbB2 mice, but also investigates cellular and systemic changes. To this end, we observed a striking decrease in mammary gland morphogenesis and proliferation, as well as the reduction of ER and RTK signaling after CR. We also report that CR inhibits luminal, MaSC-enriched and luminal progenitor mammary epithelial cell (MEC) subpopulations and suppresses MaSC self-renewal in MMTV-ErbB2 mice. Overall, our data demonstrate the potential of CR to prevent mammary tumorigenesis through the regulation of several signaling pathways that control oncogenic cellular responses. The anticancer efficacy of dietary intervention also provides a promising alternative strategy where chemotherapeutic drugs can be administered in combination with CR to improve clinical responses. Furthermore, understanding the cellular and systemic responses to changes in energy balance will facilitate the development of energy restriction mimetics.
Materials and methods

Animals and treatments
Female FVB/N-Tg MMTV-neu/ErbB2 (MMTV-ErbB2) transgenic mice were purchased from Jackson Laboratory (Bar Harbor, ME). All mice were fed AIN-93G diet ad libitum until 8 weeks of age. Mice were randomly assigned to control or CR diet groups. Control mice continued receiving the AIN-93G diet ad libitum, while the CR mice received 30% less of the average daily calories consumed by the control ad libitum-fed mice beginning at 8 weeks of age. The CR mice also received supplements to ensure that nutrient intake was equivalent between the groups. Control and CR diets continued until the mice reached 60 weeks of age or tumors exceeded 1.5 cm in diameter. Body weight of the control and CR mice was monitored every 2 weeks, beginning at 6 weeks of age, to ensure appropriate differences throughout the course of the experiment ( Figure 1A ). At 15 and 20 weeks of age, six mice from each group were euthanized for further histological and molecular analyses, as described below. To determine the tumor latency in the remaining 20 mice from each group, mammary tumor development was assessed twice a week beginning at 20 weeks of age until the conclusion of the experiment at 60 weeks of age. All animal procedures in this study were approved by the Institutional Animal Care and Use Committee.
Whole mount analysis
Left inguinal #4 mammary glands were excised from 15-, 20-and 55-weekold mice once the mice were euthanized. Then, the glands were fixed overnight at room temperature in Carnoy's solution, followed by serial washes in ethanol. The glands were stained for 12 h at room temperature with carmine alum. After the slides were washed and dehydrated in ethanol, the glands were cleared with xylene and mounted. Whole mounts were examined for ductal density using Nikon Eclipse 80i microscope and images were captured using the Nikon Elements Imaging System.
Histology
For histopathological analysis of mammary tissues from 15-week-old mice, collected tissues from the right inguinal #4 mammary glands were formalin-fixed and paraffin-embedded (FFPE), followed by hematoxylin and eosin staining. Briefly, hematoxylin was added to the FFPE tissues for 5 min, followed by washes in water, 1% HCl in ethanol and 0.2% ammonia. Then, tissue samples were incubated in eosin Y for 1 min. Finally, stained tissue samples were dehydrated in ethanol and cleared with xylene before final mounting with Permount.
5-Bromo-2′-deoxyuridine incorporation and immunohistochemistry
Twenty-week-old mice were intraperitoneally injected with 5-bromo-2′-deoxyuridine (BrdU; 3 mg/ml in 100 µl ddH 2 O) 2 h prior to euthanasia. Collected tissues from the right inguinal #4 mammary glands were prepared by FFPE for immunohistochemistry (IHC) analysis according to standard procedures. FFPE sections of collected mammary glands were deparaffinized with xylene, followed by rehydration with ethanol. Next, antigen retrieval was performed by boiling the tissue sections in citrate buffer for 30 min. Endogenous peroxidase and unspecific binding were then blocked with incubation in 3% hydrogen peroxide for 10 min, followed by DNA denaturation with 2N HCl for 30 min at 37°C. After incubation in 20% horse serum, the tissue sections were incubated in the BrdU or ERα primary antibodies overnight at 4°C while rocking. The next day, the tissue sections were washed with phosphate-buffered saline with Tween 20 and incubated in appropriate horseradish peroxidase (HRP) secondary antibodies for 1 h at room temperature. The tissues were then stained using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA) and diaminobenzidine. The sections were counterstained with hematoxylin, dehydrated and cleared. Finally, the stained sections were mounted and imaged using a Nikon Eclipse 80i microscope and NIS-Elements Microscope Imaging Software. The number of MECs with BrdU staining was recorded to determine the percentage of proliferating cells in each sample.
MEC isolation and flow cytometry analysis
The #3 mammary glands from 20-week-old mice were harvested and homogenized using a tissue chopper (Mickle Laboratory Engineering). Then, the homogenate was digested with collagenase (Roche) and hyaluronidase (Sigma, St Louis, MO) for 2 h at 37°C. The resulting primary organoids were digested further with 0.25% trypsin-ethylenediaminetetraacetic acid (Sigma) and dispase (Roche)/DNase I (Sigma) and strained through a 40-µm mesh filter. The single cell suspension of the isolated primary MECs was then used for assays as described below.
For flow cytometry analysis, the primary MECs were stained with fluorescent antibodies against lineage and cell surface markers, according to standard procedures (32) . Briefly, cells were stained with 7-aminoactinomycin D to exclude non-viable cells; purified anti-CD16/CD32 (BD Biosciences) to block Fc receptors; PE-conjugated anti-CD31 (BD Biosciences), anti-TER-119 (BioLegend, San Diego, CA) and anti-CD45 (BioLegend) to exclude endothelial, erythroid and leukocyte cells, respectively; and biotin-streptavidin-APC anti-CD24 (BD Biosciences), biotin-streptavidin-APC anti-CD61 (BD Biosciences) and FITC-conjugated anti-CD49f (BD Biosciences). FlowJo analysis software was used for gating and quantification of the individual cell populations.
Colony-forming cell assay
Primary MECs were seeded (4 × 10 3 cells per plate) in 60-mm plates and incubated in a 5% CO 2 atmosphere. After 7 days of incubation, the colonies were washed in PBS, fixed in acetone:methanol (1:1) and stained with Wright's Giemsa. Images were captured using the Nikon SMZ 745T microscope and Nikon Elements Imaging System software. The number of colonies with >50 cells was recorded for each sample. Cambridge, MA) supplemented with 10 µg/ml insulin (Sigma), 1 µg/ml hydrocortisone (Sigma), 1× B-27 (Thermo Scientific, Rockford, IL), 20 ng/ ml EGF (Stemcell Technologies), 20 ng/ml basic fibroblast growth factor (Stemcell Technologies), 4 µg/ml heparin (Stemcell Technologies) and 50 µg/ml gentamycin. The isolated MECs were cultured for 7 days to form primary mammospheres. Primary mammospheres were then counted and imaged before trypsinization. The single cell suspension of the harvested primary mammospheres was replated (1 × 10 3 cells per well) under the same conditions to form secondary spheres. After another 7 days of incubation, secondary mammospheres were counted and imaged for analysis. Mammosphere assays were performed in at least triplicate.
Mammosphere and 3D culture assays
For the 3D culture assay, primary MECs from control and CR-fed MMTV-ErbB2 mice were seeded (1.5 × 10 4 cells per well) in matrigel in 48-well plates for 7 days. Then, spheroid cultures were imaged for analysis of anchorage-independent cell growth. The 3D culture assay was performed in at least triplicate.
Western blot analysis
Tissues of the #3 mammary gland from 15-week-old mice were homogenized for the collection of protein lysate. Protein concentrations were determined with a BCA Protein Assay kit (Thermo Scientific). Fifty micrograms of protein lysates were loaded on 10-15% sodium dodecyl sulfate polyacrylamide gels. After gel electrophoresis, the separated proteins were transferred to nitrocellulose membranes and blocked with 5% milk in Tris-buffered saline with Tween 20 (TBST). The membranes were then incubated in primary antibodies diluted in 5% bovine serum albumin in TBST overnight at 4°C. The next day, the membranes were washed with TBST and incubated in appropriate HRP secondary antibodies at room temperature for 1 h before proteins were detected with an enhanced chemiluminescence kit (Thermo Scientific). Images of the protein bands were captured using a FluorChemE imaging system (Cell Biosciences).
RNA isolation and quantitative real-time PCR
Tissues of the #3 mammary gland from 15-week-old mice were harvested and snap-frozen. Then, collected tissues were homogenized for RNA isolation using an RNeasy Mini Kit (Qiagen, Valencia, CA). RNA (1 µg) was reverse transcribed according to iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) instructions. Next, quantitative real-time PCR was performed using a Bio-Rad CFX 96TM Real-Time PCR System (Bio-Rad) with the forward and reverse primers for the indicated genes (Supplementary  Table S1 , available at Carcinogenesis Online). PCR reactions were initiated with denaturation at 95°C for 5 min, followed by 40 amplification cycles at 95°C for 10 s, 60°C for 20 s and 72°C for 20 s. Melt curves were completed at 72°C for 6 s, 95°C for 5 s and 25°C for 30 s. The relative mRNA levels of each gene in the CR diet samples versus the control samples were quantified based on the cycle threshold (Ct) values and normalized to the ACTB (β-actin) internal control.
Statistical analysis
A Kaplan-Meier curve was produced to determine the tumor-free percentage of mice in each group throughout the experiment. The significant changes in tumor latency were analyzed using a log-rank test. A twosample Student's t-test, with a P-value of ≤0.05 chosen for significance, was used to compare mean significant differences between control and CR groups for all other analyses.
Results
CR increases mammary tumor latency in MMTVErbB2 transgenic mice
Previous reports have indicated that dietary interventions can affect tumor development (3, 7, 33) . As the fundamental model for cellular and molecular analyses described below, we first examined the effect of CR on body weight and mammary tumor development in MMTV-ErbB2 transgenic mice. As compared to the ad libitum-fed mice, mice with 30% CR diet starting at 8 weeks of age did not exhibit any phenotypic abnormalities besides lower body weight ( Figure 1A ). Tumorigenic analysis demonstrated that CR induced a significant delay in the appearance of palpable tumors and remarkably decreased the number of tumor-bearing mice by the end of the experiment (60 weeks of age) ( Figure 1B) . Importantly, only 15% (3/20) of the CR mice had developed palpable tumors by 60 weeks of age, while 100% (20/20) of the control mice developed palpable tumors by 55 weeks of age. Decreased tumor incidence and increased tumor latency demonstrate that CR has profound mammary tumor preventive effects in MMTV-ErbB2 transgenic mice.
CR modifies mammary morphogenesis and proliferative index in premalignant mammary tissues
Mammographic density is a surrogate marker to predict breast cancer risk in humans (34, 35) . As such, altered development/ morphogenesis of premalignant mammary glands can be indicative of mammary tumor risk in mice (36, 37) . Since palpable mammary tumors in the MMTV-ErbB2 mouse model usually first appear around 23 weeks of age, we examined the effects of CR on mammary morphogenesis in 15-and 20-week-old mice during the premalignant 'risk window' for mammary tumor development in this model. The morphogenic changes were analyzed by mammary epithelial density, ductal branching and proliferative index in mammary whole mounts. As shown in Figure 2A and B, mammary whole mounts from control mice displayed more proliferative mammary glands, as indicated by complex branching and dense mammary epithelial trees. In contrast, mammary morphogenesis in CR mice was characterized by significantly decreased mammary epithelial area/ density ( Figure 2B ) and ductal extension/branching in 15-and 20-week-old mice (Figure 2A) . Moreover, mammary tissues from CR mice displayed thinner ducts and fewer alveolar buds. Histopathological analysis indicated that mammary ducts from control mice exhibited hyperplasia, whereas mammary ducts in the CR mice displayed epithelial cell organization with thinner ductal walls ( Figure 2C ). Moreover, examination of the proliferative status of MECs with BrdU incorporation at 20 weeks of age indicated that CR significantly decreased the number of proliferative cells in the mammary tissues, as compared to the control-fed mice ( Figure 2D ). To note, the mammary glands of 55-week-old CR mice exhibited ductal outgrowth to the distal edge of the fat pads and were significantly thinner and less complex than the control mice (Supplementary Figure S1 , available at Carcinogenesis Online). These data demonstrate that CR induces profound inhibition of MEC proliferation and mammary morphogenesis.
CR inhibits MaSC/progenitor cell dynamics and alters MEC subpopulations in premalignant mammary tissues from MMTV-ErbB2 mice
The regulation of MaSCs and MEC subpopulations has been associated with modified mammary tumor risk and prevention. Analysis of MEC subpopulations and MaSC markers have been used to characterize MEC stemness in mammary tissues exposed to different preventive and risk factors. To determine CR-induced effects on the stemness of premalignant mammary tissues from MMTV-ErbB2 mice, we performed flow cytometry analysis on isolated primary MECs from 20-week-old mice that were fed the control or CR diets (Supplementary Figure S2, Figure 3A ) (38) . Using CD24/CD49f markers, we found that CR diet significantly decreased the percentage of luminal and putative MRU cells. The CD24 low
CD49f
high myoepithelial/basal cell subpopulation was increased ( Figure 3B ), which are possibly the cells responsible for maintaining ductal structure in CR mice. CR-induced inhibition of luminal and MRU cell populations may explain the modified mammary morphogenesis observed in Figure 2 .
The CD61
high CD49f high population has previously been shown to be the luminal progenitor cells that give rise to CSCs/TICs in ErbB2-overexpressing murine mammary tumors (39) . Since data shown in Figure 3A and B indicated that CR inhibited the MEC populations that are enriched with MaSCs, we postulated that CR would subsequently suppress the presence of TIC precursors/luminal progenitor cells, which are derived from MaSCs and promote tumorigenesis and metastasis (25, 40, 41) . To this end, we used CD61/CD49f cell surface markers to examine the effects of CR on TIC precursor populations in premalignant primary MECs of MMTV-ErbB2 mice. As such, CR during the premalignant 'risk window' significantly downregulated the CD61 high CD49f high population (Q2) of MECs from MMTV-ErbB2 mice ( Figure 3C and D) .
CR inhibits MaSC self-renewal and colony formation of mammary progenitor cells in MMTV-ErbB2 mice
As suggested by our flow cytometry analyses showing that CR induces MEC repopulation and inhibits MaSC stemness, we next characterized the functional properties of progenitor cells and MaSCs using colony formation and mammosphere assays, respectively. In Figure 4A , CR significantly suppressed progenitor cell numbers, as determined by reduced colony formation. CR-induced inhibition of MaSC self-renewal was demonstrated by decreased primary and secondary mammosphere formation ( Figure 4B) . Moreover, using a 3D culture assay, results indicated that CR significantly inhibits anchorage-independent cell growth of primary MECs ( Figure 4C ). These data suggest that CR-induced inhibition of MaSC and progenitor cell stemness contributes to the observed alternations in MEC subpopulations and morphogenesis during the 'risk window' for mammary tumor development.
CR attenuates ErbB2 and ER signaling pathways in premalignant mammary tissues from MMTV-ErbB2 mice
Signaling in ER and EGFR/ErbB2 pathways plays a critical role in mammary tumor development (14,15,42) . To understand the underlying mechanisms of CR-induced inhibition of tumorigenesis and MaSC/progenitor cell stemness, we examined key markers in ER and EGFR/ErbB2 oncogenic signaling pathways in premalignant mammary tissues from MMTV-ErbB2 mice. As shown in Figure 5A , CR strikingly downregulated EGFR/ErbB2 signaling as indicated by decreased EGFR and ErbB3 expression and blocked phosphorylation/activation of ErbB2 and downstream Erk1/2 and Akt. Importantly, CR also increased the expression of PTEN, a well-known tumor suppressor that functions as a critical inhibitor of PI3K (43) . Concurrently, we found that CR inhibited the ER pathway as demonstrated by moderate suppression of ERα expression and striking inhibition of ERα phosphorylation/activation ( Figure 5B ). To examine the in situ effects of CR diet on ER signaling, we performed IHC and found that number of ERα-expressing mammary cells was markedly reduced in the CR mice (Supplementary Figure S3 , available at Carcinogenesis Online), which is consistent with the reduced protein levels of total ERα in our western blotting analysis. Moreover, the expression of E2F-1 and Cyclin D1, two critical cell cycle regulators downstream of ER signaling, was also suppressed by CR. Since ER regulates the transcription of genes involved in multiple pathways, including growth factors and their receptors in particular, we further examined the mRNA levels of a panel of genes involved in ER and EGFR/ErbB2 pathways. CR significantly inhibited the transcription of ESR1 (ERα), ERBB2, EGFR, IGF1/2, IGF1R/2R, CCND1 (Cyclin D1) and GSK3β in the premalignant mammary tissues of 15-week-old MMTV-ErbB2 mice ( Figure 5C ). Since these ER-targeted genes regulate the signaling of EGFR/ErbB2 pathways, our data suggest that CR-induced concurrent downregulation of ER and EGFR/ErbB2 signaling involves cross-talk between these two pathways through ER-mediated transcriptional regulation of growth factors/receptors and ER phosphorylation via RTK signaling.
Discussion
In contrast to obesity as a risk factor for breast cancer, CR by dietary modification has been associated with decreased tumor initiation and progression (1) (2) (3) (4) (5) 23, 44) . However, the underlying mechanisms remain unclear. In our current study, we investigated the systemic effects and cellular mechanisms of CR-induced mammary tumor inhibition in the MMTV-ErbB2 transgenic mouse model, with a focus on the regulation of MaSC/ progenitor cell stemness. We found that 30% CR beginning at 8 weeks of age remarkably suppressed tumorigenesis in MMTVErbB2 mice. Importantly, we demonstrated that CR-mediated tumor inhibition was preceded by significant suppression of MaSC/progenitor cell stemness and corresponding changes in MEC subpopulations and mammary morphogenesis in the premalignant mammary tissues. The underlying mechanisms involve ER-induced inhibition of the activation and cross-talk between ER and EGFR/ErbB2 signaling pathways. These findings advance our understanding of the potential anticancer mechanisms of CR, which is important for developing CR and/ or energy restriction mimetics as cancer preventive/therapeutic strategies.
Data from both epidemiological studies and animal models support a link between CR/energy balance and reduced breast cancer risk (1) (2) (3) (4) (5) 23, 44) . As such, CR has been used alone or in combination with other preventive strategies for breast cancer prevention/intervention in different settings. Recently, Mizuno et al. (2013) reported that chronic and intermittent 25% CR diets significantly inhibited mammary tumor development in MMTVErbB2 transgenic mice, which was further enhanced in combination with eicosapentaenoic acid (23) . Rossi et al. (44) showed that CR-induced inhibition of mammary tumor development in MMTV-ErbB2 mice was associated with the suppression of ERα and ERβ expression through the induction of epigenetic reprogramming, as indicated by increased DNA methylation of ESR1 and ESR2 promoter regions. While these studies provide fundamental support and epigenetic insight into CR-mediated inhibition of mammary tumor development, the cellular mechanisms involved in these processes remain unclear. Therefore, prior to mechanistic analyses of the premalignant mammary tissues, we characterized mammary tumorigenesis in MMTVErbB2 transgenic mice with 30% CR. Our data showed that 30% CR reduced the body weight by ~27.9% at the end of the study and inhibited mammary tumor development, as indicated by a striking decrease in tumor incidence and increase in tumor latency, as compared to the ad libitum control-fed mice (Figure 1 ). Reduced mammary tumor risk was accompanied by modified morphogenesis showing decreased MEC density and proliferative index in the premalignant mammary tissues (Figure 2 ). Based on these data, outstanding questions remain regarding the molecular and cellular mechanisms that result in longer tumor latency and remarkable morphogenic changes in the premalignant tissues.
Our study focused on CR-mediated inhibition of MEC stemness in context with modified tumorigenesis. Recent advances in the CSC theory suggest that tumor development, metastasis and recurrence are mainly driven by a small population of cancer cells with stem cell-like properties (27, 45, 46) . Deregulation of tissue stem/progenitor cells promotes CSC development and tumor initiation. Therefore, studying the regulation of MaSCs/progenitor cells is critical for understanding breast cancer etiology and associated risk factors. To this end, our data demonstrate that CR induces significant alterations in MEC populations. In particular, CR induces a significant decrease in luminal cells (CD24 low MECs are the major subpopulation that constitutes the ductal lumen and alveolar structure of the mammary gland (38, 47, 48) , these data may explain the decreased MEC density and alveolar buds observed in the mammary gland whole mounts from CR mice (Figure 2 ). The decrease in the MRU cell population also suggests that CR inhibits the dynamics of MaSC self-renewal. In context with reports that CD61 high cell population ( Figure 3) suggests that CR may inhibit TIC development resulting in decreased/delayed tumor development. Consistent with our phenotypic characterization results, data from functional assays, including CFC, mammosphere and 3D colony/anchorageindependent growth, further demonstrated that CR decreased luminal progenitor cell numbers and inhibited MaSC selfrenewal in the premalignant mammary tissues (Figure 4) . To our knowledge, we are one of the first groups to use a MaSC/tissue hierarchy approach to study CR-mediated prevention of ErbB2-overexpressing mammary tumors in vivo. Taken together, our data demonstrate that CR-induced inhibition of MEC stemness and subsequent mammary reprogramming in the premalignant tissues are intrinsic components of the mechanism underlying CR-mediated mammary tumor prevention.
Since MaSCs and luminal progenitor cells are likely targets for malignant transformation of MECs (27, 46, 49) and TICs/CSCs are associated with aggressive cancer phenotypes and poor therapeutic responses (40, 41, 45) , our results indicating that CR induces MaSC reprogramming are of pivotal importance for understanding the factors that contribute to malignancy and for developing novel breast cancer preventive and treatment strategies. These findings warrant further analysis of CR-induced regulation of individual MEC subpopulations to reveal more specific gene expression patterns. Our results may also help to design more effective breast cancer preventive strategies, including CR and other MaSC-targeting agents. Further molecular analyses will facilitate the development of novel preventive agents/strategies that mimic energy restriction. For example, we have previously reported that metformin, an energy restriction mimetic, also selectively inhibits the putative MaSC-and TIC precursor-enriched MEC populations and stemness in premalignant mammary tissues from MMTV-ErbB2 mice (29) . While we have demonstrated the effects of CR on individual cell populations ( Figure 3 ) and in situ expression of ERα in the premalignant mammary tissues (Supplementary Figure S3 , available at Carcinogenesis Online), further analyses of individual cell populations, in particular the CD24 low CD49f high basal compartment, with more specific markers and functional assays will refine our findings to advance our understanding of CR-induced MEC reprogramming. Importantly, these analyses of individual cell populations would reveal how CR differentially affects gene and protein expression, and how these differential expression profiles in individual cell subtypes are associated with the regulation of mammary gland development and tumorigenesis.
Previously, we reported that the anti-diabetes drug metformin, which shares anticancer mechanisms with CR, inhibits TICs in ErbB2-overexpressing breast cancer cells through the suppression of RTK/ErbB2 signaling (29) . Recent reports further show that CR induces ERα and ERβ downregulation through epigenetic mechanisms (44) . Our molecular analyses of ER and EGFR/ErbB2 pathways indicate that CR induces concurrent inhibition of both pathways, and this regulation involves both altered gene expression and decreased phosphorylation/activation of key markers in each pathway ( Figure 5 ). In context with previous studies indicating that ER-RTK cross-talk involves the regulation of ERα phosphorylation/activation by Akt and Erk, as well as ER-mediated transcription of growth factor ligands and their receptors, our findings suggest that CR inhibits ER-RTK cross-talk. This was further supported by our data showing that CR-induced downregulation of mRNA levels of growth factor ligands and their receptors, such as EGFR, ERBB2, IGF1/2 and IFG1R/2R, which are also ER-targeted genes. Our data reveal the complex regulatory networks of CR-mediated mammary tumor prevention that involve epigenetic, transcriptional and posttranslational mechanisms. Since ER and ErbB2 are master regulators involved in mammary development and carcinogenesis, CR-induced inhibition of ER-ErbB2 cross-talk and the consequent cellular responses are likely contributors to CR-mediated inhibition of MEC stemness and mammary tumor development. In future studies, the molecular connections between these cellular responses need to be further investigated.
In conclusion, we have demonstrated that CR-induced prevention of mammary tumor development in MMTV-ErbB2 transgenic mice is associated with MEC reprogramming and inhibited MaSC/progenitor cell stemness. Luminal progenitor cells and the MRU subpopulation appear to be the targets of CR-induced MEC reprogramming, which may contribute to the observed decrease/delay in mammary tumor development. Molecular analyses indicate that CR-induced inhibition of ER signaling and ER-ErbB2 cross-talk is an important mediator of the modified cellular responses and mammary tumor risk. Our findings support the concept of targeting MaSCs/TICs in breast cancer prevention strategies. Future analysis of CR-induced gene expression in individual MEC subpopulations will provide more insight into the mechanisms of CR-induced MEC reprogramming and tumor prevention and will facilitate the development of novel preventive agents/strategies that will enhance the efficacy of CR-mediated breast cancer prevention.
